64 Participants NeededMy employer runs this trial

RE104 for Anxiety

Recruiting at 11 trial locations
MP
Overseen ByMark Pollack Chief Medical Officer, M.D.
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Reunion Neuroscience Inc
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests whether a single dose of RE104 for Injection can reduce anxiety symptoms in people with Generalized Anxiety Disorder (GAD). Participants will receive either RE104 or a placebo (a harmless substance resembling the treatment) to compare effects. This trial suits those diagnosed with GAD who experience regular anxiety impacting daily life. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

Is there any evidence suggesting that RE104 for Injection is likely to be safe for humans?

Earlier research found RE104 to be safe and easy to handle when administered as a single shot. This study showed no serious side effects, which is reassuring. Another study with a 30 mg dose of RE104 also found it was well-tolerated, with only mild side effects reported. Serious negative effects were rare or absent. These findings suggest that RE104 could be a safe option for those considering participation in a clinical trial for anxiety.12345

Why do researchers think this study treatment might be promising for anxiety?

Unlike the standard treatments for anxiety, which often include oral medications like SSRIs or benzodiazepines, RE104 is administered as a single subcutaneous injection. This is a novel delivery method that could offer quicker onset of effects compared to traditional oral pills. Researchers are particularly excited about RE104 because it may work differently, potentially targeting anxiety through a unique mechanism of action that could provide relief when other medications fall short. This innovative approach could mean faster, more efficient treatment options for those struggling with anxiety.

What evidence suggests that RE104 for Injection might be an effective treatment for anxiety?

Research has shown that RE104 for Injection may help treat anxiety. In earlier studies, a single 30 mg dose of RE104 quickly and lastingly improved depression symptoms. This trial will test a 30 mg dose of RE104 for its potential effects on anxiety, as anxiety and depression often share symptoms. Specifically, 71.4% of participants in that study reported significant relief from their symptoms after using RE104. Additionally, the treatment proved safe, with no serious side effects reported. These findings suggest that RE104 could be an effective and safe option for relieving anxiety.23456

Who Is on the Research Team?

MP

Mark Pollack, M.D.

Principal Investigator

Reunion Neuroscience Inc

Are You a Good Fit for This Trial?

This trial is for adults diagnosed with Generalized Anxiety Disorder who are either on stable antidepressants or therapy, or willing to delay starting them. Participants must not be pregnant or planning pregnancy and should be able to follow study requirements.

Inclusion Criteria

I am not pregnant or planning to become pregnant.
* Is willing and able to comply with the conditions and requirements of the study
I have been diagnosed with Generalized Anxiety Disorder.
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive a single subcutaneous injection of either 30 mg RE104 or placebo

Single dose
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

12 weeks
Visits at Weeks 1, 2, 4, 8, and 12

What Are the Treatments Tested in This Trial?

Interventions

  • RE104 for Injection

Trial Overview

The study tests whether a single dose of RE104 injection can reduce anxiety symptoms compared to a placebo (inactive treatment) in people with Generalized Anxiety Disorder.

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Placebo Group

Group I: 30 mg RE104Experimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Reunion Neuroscience Inc

Lead Sponsor

Trials
2
Recruited
90+

Citations

Met Primary Endpoint with 30mg Dose of RE104 ...

โ€œThese data demonstrate the totality of RE104's rapid and durable impact โ€“ across a range of physician- and patient-reported outcomes and ...

RE104 Safety and Efficacy Study in Adjustment Disorder in ...

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed ...

RE104 30 mg demonstrates efficacy and safety in new ...

A single 30 mg dose of RE104 produced rapid and sustained reductions in depressive symptoms in women with moderate-to-severe postpartum ...

Safety, Tolerability, Pharmacokinetics, and ... - PMC

SC doses of RE104 were generally safe up to 40 mg with no serious adverse events (AEs) or deaths. Most AEs occurred acutely under supervision ...

Reunion Neuroscience Announces Program Updates and ...

... RE104 can safely deliver clinically meaningful improvements in depression and anxiety scores. These results unlock a blockbuster opportunity in PPD, where ...

RE104: A Novel, Fast-Acting Psychedelic for Postpartum ...

Phase 1 study showed RE104's safety and tolerability, with no serious adverse effects, supporting its use in postpartum depression treatment.